Seiko Solutions' AI Knowledge Platform "Seiko Futureworks" Adopted for Proofreading Pharmaceutical Information Materials by Pharma International

Seiko Solutions Corporation (President and CEO: Jun Sekine, Headquarters: Chiba City, Chiba Prefecture, hereinafter Seiko Solutions) announced that its AI knowledge platform "Seiko Futureworks" has been adopted for the proofreading of pharmaceutical information materials by Pharma International Inc. (President and CEO: Masaki Yamagata, Headquarters: Chuo-ku, Tokyo, hereinafter Pharma International).

Both companies jointly conducted a trial for approximately three months from December 2025, verifying the effectiveness of AI proofreading on a total of 8 materials, including patient booklets, interview records, pamphlets, and academic conference records, from multiple perspectives such as initial reading, manuscript collation, material consistency, and specialized terminology. After two tuning sessions, the system achieved improved detection accuracy and reduced false positives, and full-scale operations began in April 2026.

For this adoption, Pharma International was responsible for providing on-site knowledge of proofreading operations and evaluation, while Seiko Solutions provided the Seiko Futureworks platform, implementation support, tuning, and operational support.

[Background]

Pharmaceutical information materials play a crucial role in conveying accurate information about the efficacy and safety of drugs to healthcare professionals and patients. Proofreading requires confirmation from a wide range of perspectives, including typographical errors, inconsistencies in notation, uniformity of terminology, consistency, collation with manuscripts and original texts, and compliance with creation guidelines.

Pharma International, which has over 50 pharmaceutical companies as clients and plans and produces more than 4,000 pharmaceutical information materials annually, has continuously promoted initiatives to ensure quality, such as establishing an internal education system for thorough regulatory compliance. However, to achieve further quality improvement and operational efficiency, they decided to introduce Seiko Futureworks, which enables accurate AI reviews that reflect the company's unique rules and knowledge.

<System Usage Flow>

Value and Effects of Implementation

Seiko Futureworks supports multiple aspects, including initial reading (comprehensively checking for typographical errors, notation variations, terminology consistency, and content consistency from dozens of check points), manuscript collation, material consistency, and specialized terminology. Additionally, it features a "Free Proofreading Mode" that allows proofreaders to freely instruct proofreading from their own perspectives, enabling flexible responses to individual project needs.

Verification during the trial period achieved high detection accuracy that can complement human proofreading, and proofreading results with fewer false positives, suppressing hallucinations (incorrect suggestions based on inference). In the operational field, high-speed processing that completes the proofreading of materials of about 100 pages in a few minutes contributes to quality improvement and operational efficiency.

In full-scale use, customers have commented that it is effective in reducing the burden of the initial reading and proofreading.

Features of Seiko Futureworks

Seiko Futureworks is an AI knowledge platform that can reflect expert knowledge and unique rules within a company into generative AI. This service enables practical support even in the highly specialized and rigorous field of proofreading pharmaceutical information materials due to the following features:

Reflects company-specific rules and knowledge: It incorporates business documents, past productions, internal rules, glossaries of specialized terms, etc., and returns proofreading results optimized for the company. Multi-faceted review by multiple expert AIs (agents): Specialized agents are set up for each proofreading perspective to minimize detection omissions. Intuitive UI using natural language: Simply upload the material and say "Please proofread" to use it. Zero Trust-based security: Operates in a dedicated cloud environment for customers, ensuring secure handling of confidential information. Overview of Full-Scale Operation and Future Initiatives

Pharma International began full-scale operation of Seiko Futureworks in April 2026. In full-scale operations, the aim is to establish a high-quality proofreading process that combines the strengths of AI with the expert knowledge of proofreaders, by clearly defining the roles where AI serves as the primary check and humans make the final judgment.

Both companies will continue to collaborate, advancing the continuous tuning of AI agents and functional improvements based on feedback from the field, gradually expanding the scope of materials and proofreading perspectives, and further improving detection accuracy.

[Comment from Pharma International]

Takaaki Kimura, Director of the Pharmaceutical Information Solutions Department, Pharma International Inc.

"Our company plans and produces over 4,000 pharmaceutical information materials annually, and we have been implementing various initiatives to improve quality. As part of these efforts, we introduced Seiko Futureworks in April 2026. Through joint tuning during the trial period, we achieved high detection accuracy while suppressing false positives. We expect that by combining proofreading by experienced proofreaders with AI proofreading, we can achieve both speed and quality improvement in proofreading. Pharma International will continue to change and evolve to provide services that are compatible with the 'AI era,' and deliver even faster and higher quality support to our clients, the pharmaceutical companies."

[Overview of Pharma International Inc.]

Company Name: Pharma International Inc.

Location: Chuo-ku, Tokyo

President and CEO: Masaki Yamagata

URL: https://www.pharma.co.jp/

Business Description: A communication agency specializing in healthcare products, primarily prescription drugs. With over 50 pharmaceutical companies as clients, it plans and produces over 4,000 pharmaceutical information materials and digital content annually.

Seiko Futureworks Product Page:

https://www.seiko-sol.co.jp/products/ai_platform/lp/

*Seiko Futureworks is a registered trademark of Seiko Group Corporation.

*Other product names mentioned in this text are registered trademarks or trademarks of their respective companies.